Cell therapy company Immusoft Corporation announced on Wednesday the election of Robert Hayes, PhD as its chief scientific officer.
Dr Hayes will lead the company's preclinical research and spearhead the near-term advancement of ISP-001 for the treatment of Mucopolysaccharidosis type I (MPS I) and additional Immune System Programming (ISP) candidates into clinical development.
Most recently, Dr Hayes was the head of Biologics at Amgen Inc (NASDAQ: MGN), a multinational biopharmaceutical company.
Previously, Dr Hayes has worked as vice president & venture leader of Centyrex, a biotech Venture within Janssen R&D, as well as senior director of Protein Engineering at Johnson & Johnson and Director of Antibody Engineering at Xencor.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA